Trevi Therapeutics (TRVI) EBT (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly EBT came in at -$13.2 million in Q1 2026, down 27.64% year-on-year from -$18.3 million in Q1 2025, and down 58.57% quarter-over-quarter from -$8.3 million in Q4 2025.
Trevi Therapeutics (TRVI) EBT (2018 - 2026) Analysis & Trends
Trevi Therapeutics' EBT history runs 9 years deep, the most recent figure standing at -$13.2 million for Q1 2026.
- On a quarterly basis, EBT fell 27.64% year-over-year to -$13.2 million in Q1 2026; TTM through Mar 2026 was -$45.7 million, a 3.59% increase from a year earlier, with the FY2025 full-year figure at -$42.8 million, up 10.68% from the prior year.
- EBT declined to -$13.2 million in Q1 2026 per TRVI's latest filing, from -$8.3 million in the prior quarter.
- Across five years, EBT topped out at -$5.5 million in Q4 2022 and bottomed at -$13.3 million in Q3 2024.
- The 5-year median for EBT is -$8.3 million (2025), against an average of -$9.5 million.
- Across the five-year window, EBT soared 35.2% in 2022 and plunged 72.26% in 2024, its largest moves.
- Year by year, EBT stood at -$5.5 million in 2022, then slumped by 41.23% to -$7.8 million in 2023, then sank by 46.08% to -$11.4 million in 2024, then grew by 26.91% to -$8.3 million in 2025, then sank by 58.57% to -$13.2 million in 2026.
- Per Business Quant, the three latest TRVI EBT figures stand at -$13.2 million (Q1 2026), -$8.3 million (Q4 2025), and -$11.8 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - | -13.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.21 Mn |
| Dec 31, 2025 | -8.33 Mn |
| Sep 30, 2025 | -11.82 Mn |
| Jun 30, 2025 | -12.32 Mn |
| Mar 31, 2025 | -10.35 Mn |
| Dec 31, 2024 | -11.40 Mn |
| Sep 30, 2024 | -13.27 Mn |
| Jun 30, 2024 | -12.36 Mn |
| Mar 31, 2024 | -10.91 Mn |
| Dec 31, 2023 | -7.80 Mn |
| Sep 30, 2023 | -7.71 Mn |
| Jun 30, 2023 | -7.18 Mn |
| Mar 31, 2023 | -6.41 Mn |
| Dec 31, 2022 | -5.53 Mn |
| Sep 30, 2022 | -8.27 Mn |
| Jun 30, 2022 | -8.06 Mn |
| Mar 31, 2022 | -7.33 Mn |
| Dec 31, 2021 | -8.53 Mn |
| Sep 30, 2021 | -7.25 Mn |
| Jun 30, 2021 | -9.80 Mn |